FCA Perils Mount For Drugmakers As DOJ Gets Personal

Law360, New York (February 5, 2014, 7:38 PM EST) -- The U.S. Department of Justice is increasingly pushing to directly monitor drugmakers long after False Claims Act cases are closed and hold executives personally liable for future misconduct, a development that attorneys say raises the stakes of fraud investigations to new heights.

Recent criminal matters involving Abbott Laboratories, GlaxoSmithKline PLC and Par Pharmaceutical Cos. Inc. have, for example, resulted in plea agreements under which executives must certify for several years that any subsequent illicit marketing has been disclosed.

“I have been telling clients this is potentially...
To view the full article, register now.